

# Contents

<b>Dedication</b>	<b>v</b>
<b>Acknowledgements</b>	<b>vii</b>
<b>Chapter 1. 50th Anniversary of Artificial Cells</b>	<b>1</b>
1.1. Background . . . . .	1
1.2. Starting with Artificial Red Blood Cells . . . . .	2
1.3. Further Research and the First Routine Clinical Use of Artificial Cells . . . . .	5
1.4. Importance of Progress in Parallel Areas of Biotechnology, Molecular Biology, and Regenerative Medicine . . . . .	7
1.5. Historical Milestones . . . . .	7
<b>Chapter 2. Basic Principles</b>	<b>12</b>
2.1. Basic Features of Artificial Cells . . . . .	12
<i>Basic features of early artificial cells</i> . . . . .	12
<i>Present status of the basic features of artificial cells of macro, micron, nano and molecular dimensions</i> . . . . .	14
2.2. Nanotechnology and Nanobiotechnology . . . . .	15
<i>Nanobiotechnology and artificial cells</i> . . . . .	15
<i>Nanobiotechnology and the assembling of hemoglobin with enzymes that remove oxygen radicals</i> . . . . .	17
<i>Nanobiotechnology for the assembling of hemoglobin with other enzymes</i> . . . . .	17

	<i>Conjugation of polymer with proteins</i> . . . . .	18
2.3.	Cell Homogenate, Organelle, Enzymes and Multienzyme Systems . . . . .	18
	<i>Cell homogenate</i> . . . . .	18
	<i>Enzymes and enzyme therapy</i> . . . . .	19
	<i>Multienzyme systems with cofactor recycling</i> . . . . .	20
2.4.	Artificial Cells Containing Intracellular Compartments . . . . .	21
2.5.	Artificial Cells Containing Biologics and Magnetic Material . . . . .	22
2.6.	Cells, Islets, Stem Cells, Genetically-engineered Cells and Microorganisms . . . . .	22
	<i>Artificial cells containing cells</i> . . . . .	22
	<i>Stem cells</i> . . . . .	24
	<i>Genetically-engineered cells</i> . . . . .	24
2.7.	Artificial Cells Containing Bioadsorbents . . . . .	25
2.8.	Research on Membrane Model Systems . . . . .	27
2.9.	Cell Physiology . . . . .	28
2.10.	Drug Delivery . . . . .	28
	<i>Polymeric semipermeable microcapsules</i> . . . . .	28
	<i>Biodegradable polymeric artificial cells, nanoparticles, nanocapsules</i> . . . . .	29
	<i>Liposomes — lipid membrane artificial cells</i> . . . . .	29
2.11.	Other Systems . . . . .	30
<b>Chapter 3. Oxygen Carriers Based on Nanobiotechnology</b>		<b>31</b>
3.1.	Introduction . . . . .	31
3.2.	Hemoglobin as Oxygen Carrier . . . . .	32
3.3.	Modified Hb . . . . .	32
	<i>PolyHb based on nanobiotechnology (Fig. 3.1)</i> . . . . .	33
	<i>Conjugated Hb (Fig. 3.1)</i> . . . . .	34
	<i>Intramolecularly crosslinked single tetrameric Hb (Fig. 3.1)</i> . . . . .	35
	<i>Recombinant human Hb (Fig. 3.1)</i> . . . . .	35
	<i>Present status</i> . . . . .	35
3.4.	PolyHb in Clinical Trials . . . . .	36
3.5.	Nanobiotechnology-based PolyHb Compared with other Modified Hb . . . . .	39
	<i>Vasopressor effects</i> . . . . .	39

	<i>Theories why vasopressor effects are observed only in some types of modified Hb?</i> . . . . .	39
	<i>Effects of tetrameric Hb on vasoactivity and ECG</i> . . . . .	40
3.6.	PolyHb with <2% Tetrameric Hb . . . . .	43
3.7.	Nanobiotechnology and Immunogenicity . . . . .	45
	<i>Antigenicity measured as antibody titers</i> . . . . .	45
	<i>Effects of infusion</i> . . . . .	46
3.8.	Bridging the Gap between Safety Studies in Animal and Humans . . . . .	48
	<i>In vitro screening test using human plasma before use in humans</i> . . . . .	48
	<i>Basic principles of screening test</i> . . . . .	49
	<i>Use in research</i> . . . . .	50
	<i>Use in industrial production</i> . . . . .	50
	<i>Correlation of in vitro complement activation to clinical symptoms</i> . . . . .	51
	<i>Clinical trials and use in humans</i> . . . . .	52
3.9.	Design of Animal Study for Hemorrhagic Shock . . . . .	52
	<i>Hemorrhagic shock model</i> . . . . .	52
	<i>Experimental designs</i> . . . . .	53
3.10.	General Discussions . . . . .	55
3.11.	Methods and Procedures . . . . .	56
	<i>Special method for preparation of PolyHb containing low levels of tetrameric Hb (0.2 to 2%)</i> . . . . .	56
	<i>In vitro screening test using human plasma before use in humans</i> . . . . .	58
	<i>Animal study on hemorrhagic shock and exchange transfusion</i> . . . . .	59
 <b>Chapter 4. A Nanobiotechnologic Therapeutic that Transports Oxygen and Remove Oxygen Radicals: For Stroke, Hemorrhagic Shock and Related Conditions</b>		<b>62</b>
4.1.	Introduction . . . . .	62
4.2.	Ischemia-Reperfusion . . . . .	62
4.3.	PolyHb-CAT-SOD . . . . .	63
4.4.	Enzyme Activities after Intravenous Injections . . . . .	64
	<i>Plasma Hb concentration</i> . . . . .	64

	<i>SOD activity in plasma</i> . . . . .	65
	<i>CAT activity in plasma</i> . . . . .	66
	<i>Discussions</i> . . . . .	66
4.5.	Tests in Animal Models for Stroke and Hemorrhagic Shock . . .	67
4.6.	Ischemia-Reperfusion of the Intestine . . . . .	67
	<i>Severe hemorrhagic shock and the intestine</i> . . . . .	67
	<i>Test on effects of reperfusion on ischemic intestine</i> . . . . .	68
4.7.	Test in Combined Hemorrhagic Shock and Stroke Rat Model . .	69
	<i>Prolonged hemorrhagic shock and stroke model</i> . . . . .	69
	<i>Rat model of combined hemorrhagic shock and stroke</i> . . . . .	71
	<i>Duration of stroke and reperfusion injuries</i> . . . . .	71
	<i>Effects of different solutions on reperfusion injuries</i> . . . . .	72
	<i>Disruptions of blood-brain barrier</i> . . . . .	72
	<i>Brain edema</i> . . . . .	73
4.8.	Discussion . . . . .	74
4.9.	Preparation and Characterization . . . . .	75
	<i>Method of preparation</i> . . . . .	75
	<i>Molecular characterization of PolyHb-CAT-SOD</i> . . . . .	75
	<i>Oxygen dissociation curve</i> . . . . .	77
	<i>Effects of the crosslinking procedure on metHb formation</i> . . .	77
4.10.	<i>In Vitro Studies of the Antioxidant Properties of Crosslinked HB-</i>	
	<i>SOD-CAT</i> . . . . .	78
	<i>Scavenging of superoxide (<math>O_2^{\bullet -}</math>)</i> . . . . .	79
	<i>Scavenging of hydrogen peroxide (<math>H_2O_2</math>)</i> . . . . .	80
	<i>Effects of oxidative challenge on the degradation of Hb and iron</i>	
	<i>release in PolyHb and PolyHb-CAT-SOD</i> . . . . .	81
	<i>Absorbance spectra and Hb degradation</i> . . . . .	81
	<i>Release of iron</i> . . . . .	83
	<i>Lipid peroxidation and salicylate hydroxylation</i> . . . . .	84
4.11.	Methods and Procedures . . . . .	85
	<i>Preparation of PolyHb-SOD-CAT</i> . . . . .	85
	<i>Measurement of SOD activity</i> . . . . .	86
	<i>Measurement of CAT activity</i> . . . . .	87
	<i>Hydrogen peroxide scavenging</i> . . . . .	87
	<i>Ratio of SOD/CAT and Hb oxidation</i> . . . . .	87
	<i>Measurement of FerrylHb</i> . . . . .	87

<i>Iron release study</i> . . . . .	88
<i>Circulation time studies</i> . . . . .	88
<i>Rat model of intestinal ischemia-reperfusion</i> . . . . .	89
<i>Measurement of oxygen radical</i> . . . . .	89
<i>Combined hemorrhagic shock and transient global cerebral ischemia-reperfusion</i> . . . . .	90
<b>Chapter 5. Nanotechnology-based Artificial Red Blood Cells (RBCs)</b>	<b>93</b>
5.1. Introduction . . . . .	93
5.2. Micron Dimension Artificial RBCs (ARBCs) with Ultrathin Polymeric Membrane . . . . .	95
<i>Hemoglobin</i> . . . . .	95
<i>Carbonic anhydrase</i> . . . . .	95
<i>Catalase</i> . . . . .	97
<i>Immunological studies</i> . . . . .	97
5.3. Intravenous Injection of ARBCs . . . . .	98
<i>Polymeric membrane artificial RBCs 1 micron and larger</i> . . . . .	98
<i>Neuraminic acid and circulation time of red blood cells</i> . . . . .	99
<i>Effects of surface charge of polymeric particles on circulation time</i> . . . . .	101
<i>Artificial rbc's with sulfonated nylon membrane</i> . . . . .	101
<i>Polysaccharide incorporation</i> . . . . .	102
<i>Summary</i> . . . . .	103
5.4. Submicron Lipid Membrane Artificial RBCs (LEH) . . . . .	104
<i>Composition and preparation</i> . . . . .	105
<i>Methemoglobin</i> . . . . .	106
5.5. LEH in Animal Studies . . . . .	107
<i>Circulation time after infusion</i> . . . . .	107
<i>Safety of lipid membrane artificial rbc's</i> . . . . .	108
<i>Efficacy in exchange transfusion, hemorrhagic shock and hemodilution</i> . . . . .	109
<i>Summary</i> . . . . .	110
5.6. Nanodimension Biodegradable Polymeric Membrane RBCs . . . . .	110
<i>Introduction</i> . . . . .	110
<i>Nanodimension biodegradable polymeric membrane artificial rbc's</i> . . . . .	111

	<i>Safety and reasons for selection of polyesters as the biodegradable polymer membrane . . . . .</i>	112
5.7.	Characterization of Nano Artificial RBCs . . . . .	113
	<i>Electromicroscopic appearance . . . . .</i>	113
	<i>Size distribution of polylactide membrane artificial rbc's . . . . .</i>	113
	<i>Other properties . . . . .</i>	114
	<i>Steady shear viscosity determination . . . . .</i>	115
5.8.	Safety and Efficacy of Nano Artificial RBCs . . . . .	115
	<i>Amount and fate of PLA membrane . . . . .</i>	115
	<i>Efficiency in nanoencapsulating hemoglobin . . . . .</i>	117
	<i>Oxygen affinity, Hill coefficient and Bohr effect . . . . .</i>	117
	<i>Enzymes and multienzymes . . . . .</i>	118
	<i>Nano artificial rbc's containing metHb reductase system . . . . .</i>	119
	<i>Nano artificial rbc's permeable to reducing factors . . . . .</i>	120
	<i>Enzymes and multienzymes in PLA nano artificial rbc's . . . . .</i>	121
5.9.	Circulation Time of Nano Artificial RBCs . . . . .	121
	<i>Circulation half-life of nano PLA artificial rbc's . . . . .</i>	121
	<i>Different types of PEG-PLA copolymers for nano artificial rbc's . . . . .</i>	121
	<i>Analysis of results . . . . .</i>	126
	<i>Relevance for clinical application in humans . . . . .</i>	127
5.10.	General . . . . .	127
5.11.	Method of Preparation of Biodegradable Polymeric Nano Artificial RBCs . . . . .	128

## **Chapter 6. Use of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels 130**

6.1.	Introduction . . . . .	130
	<i>General . . . . .</i>	130
	<i>Enzyme replacement therapy . . . . .</i>	132
6.2.	Acatlasemia: Congenital Defect in the Enzyme Catalase . . . . .	132
6.3.	Preliminary Study on the Use of Catalase Artificial Cells to Replace Defective Catalase in Acatlasemia . . . . .	133
	<i>Implantation of catalase artificial cells . . . . .</i>	133
	<i>Catalase artificial cells retained in a chamber for body fluid perfusion . . . . .</i>	135

6.4.	<i>In Vivo</i> Kinetics of Catalase Artificial Cells for Acatlasemic Mice . . . . .	135
	<i>Summary</i> . . . . .	135
	<i>Methods of preparation of catalase artificial cells and experimental procedures</i> . . . . .	136
	<i>Characteristics of acatalasemic mice</i> . . . . .	136
	<i>Kinetics of recovery of injected perborate</i> . . . . .	136
6.5.	Immunological Studies on Catalase Artificial Cells in Acatlasemic Mice . . . . .	137
	<i>Effects of immunizing doses of catalase solution and catalase artificial cells on antibody production</i> . . . . .	137
	<i>Permeability of membrane of collodion artificial cells to catalase antibody</i> . . . . .	138
	<i>Response of immunized acatalasemic mice to injections of catalase artificial cells or catalase solution</i> . . . . .	139
	<i>Appearance of catalase activity in the blood after injection of catalase solution or catalase artificial cells</i> . . .	140
6.6.	Conclusion from Results of Basic Study Using the Acatlasemic Mice Model . . . . .	141
6.7.	Oral Xanthine Oxidase Artificial Cells in a Patient with Lesch- Nyhan Disease . . . . .	142
	<i>Volume ratio of artificial cells/substrate solution</i> . . . . .	143
	<i>Effects of pH on enzyme activity</i> . . . . .	144
	<i>Patient with Lesch-Nyhan disease</i> . . . . .	144
6.8.	Conclusion Based on Study . . . . .	146
6.9.	Phenylketonuria: Genetic Defect in Enzyme Phenylalanine Hydroxylase . . . . .	147
	<i>Phenylketonuria</i> . . . . .	147
	<i>Enzyme replacement therapy</i> . . . . .	147
	<i>Oral PAL artificial cells for PKU based on novel theory of enterorecirculation of amino acids</i> . . . . .	148
6.10.	Research Leading to Proposal of Enterorecirculation of Amino Acids . . . . .	149
	<i>Classical theory of the main source of amino acids in the intestinal lumen</i> . . . . .	149
	<i>Research to test the classical theory</i> . . . . .	149

	<i>Animals on 24 h of protein-free diet</i> . . . . .	149
	<i>Results of study</i> . . . . .	149
	<i>Proposed theory of extensive entero-recirculation of amino acids</i> . . . . .	150
6.11.	Oral Enzyme Artificial Cells for Genetic Enzyme Defects that Result in Elevated Systemic Amino Acid Levels . . . . .	152
	<i>General design for study of use of oral PAL artificial cells in PKU rats</i> . . . . .	152
	<i>Methods of preparation of catalase artificial cells and experiment procedures</i> . . . . .	154
	<i>Phenylketonuria rat model</i> . . . . .	154
	<i>Intestinal phenylalanine</i> . . . . .	154
	<i>Plasma PHE levels in PKU rats</i> . . . . .	155
	<i>CSF cerebrospinal fluid in PKU rats</i> . . . . .	155
	<i>Growth as shown by body weight changes</i> . . . . .	155
	<i>Congenital PKU mice model</i> . . . . .	157
	<i>Summary discussion</i> . . . . .	158
	<i>Oral enzyme artificial cells to deplete other amino acids</i> . . . . .	158
 <b>Chapter 7. Enzyme Artificial Cells in Substrate-dependent Tumors and Activation of Prodrug</b>		<b>160</b>
7.1.	Introduction . . . . .	160
7.2.	Asparaginase in Lymphosarcoma and Lymphoblastic Leukemia	161
7.3.	Asparaginase Artificial Cells for Lymphosarcoma . . . . .	162
	<i>Asparaginase artificial cells on 6C3HED lymphosarcoma in mice (Fig. 7.2A)</i> . . . . .	162
	<i>Effects on plasma asparagine level</i> . . . . .	164
	<i>Asparaginase activities in the body</i> . . . . .	165
	<i>Asparaginase does not leak out of artificial cells after injection</i> . . . . .	166
	<i>Discussions</i> . . . . .	167
7.4.	Crosslinking Asparaginase to Hemoglobin (PolyHb-Asparaginase) . . . . .	168
7.5.	Crosslinking of Asparaginase to Polymer (Polyethylene Glycol — PEG) . . . . .	170
7.6.	PolyHb-Tyrosinase Artificial Cells for Melanoma . . . . .	172

<i>Introduction</i> . . . . .	172
<i>Polyhemoglobin-tyrosinase for melanoma</i> . . . . .	172
<i>Studies on optimization, in vitro and in vivo</i> <i>characterization</i> . . . . .	176
<i>Summary</i> . . . . .	178
7.7. Tyrosinase Artificial Cells by Oral Route . . . . .	179
<i>Introduction</i> . . . . .	179
<i>Effects of Long-term Oral Administration of Polymeric</i> <i>Microcapsules Containing Tyrosinase on Maintaining</i> <i>Decreased Systemic Tyrosine Levels in Rats</i> . . . . .	180
<i>Enzyme kinetics</i> . . . . .	182
7.8. Discussions on PolyHb-Tyrosinase and Tyrosinase Artificial Cells . . . . .	185
7.9. Enzyme Artificial Cells for Activating Prodrugs . . . . .	186
<i>Introduction</i> . . . . .	186
<i>Clinical trial results</i> . . . . .	187
7.10. Materials and Methods . . . . .	188
<i>Asparaginase artificial cells</i> . . . . .	188
<i>PolyHb-tyrosinase in melanoma</i> . . . . .	189
<i>Preparation of PolyHb-tyrosinase</i> . . . . .	189
<i>Determination of tyrosinase activity</i> . . . . .	190
<i>Effects of intravenous injection of PolyHb-tyrosinase in rats</i> . . . . .	190
<i>B16-F10 melanoma cells and culture conditions</i> . . . . .	191
<i>Intravenous injection of PolyHb-tyrosinase in normal mice</i> . . . . .	191
<i>B16F10 melanoma bearing mice model</i> . . . . .	191
<i>Oral tyrosinase artificial cells</i> . . . . .	192
<i>Materials</i> . . . . .	192
<i>Control artificial cells</i> . . . . .	192
<i>Tyrosinase artificial cells</i> . . . . .	192
<i>In vitro studies using rat intestinal juice</i> . . . . .	193
<i>Animal studies</i> . . . . .	193
<b>Chapter 8. Artificial Cells for Cell Encapsulation</b> . . . . .	<b>195</b>
8.1. Introduction . . . . .	195
8.2. Artificial Cells Containing Islets, Liver Cells, Endocrine Cells and Others . . . . .	198
<i>Artificial cells containing islets</i> . . . . .	198

	<i>Artificial cells containing hepatocytes</i> . . . . .	202
	<i>Other areas</i> . . . . .	203
8.3.	Challenges of Artificial Cell Encapsulated Cells in Therapy . . .	203
	<i>Availability of cells</i> . . . . .	203
	<i>Mass transfer, biocompatibility and stability</i> . . . . .	204
	<i>Cell protrusion or entrapment in artificial cell membrane</i> . . .	205
	<i>Method to prevent cell protrusion or entrapment in artificial cell membrane</i> . . . . .	207
	<i>Other improvements to microencapsulation method</i> . . . . .	207
	<i>Capillary fiber cell encapsulation</i> . . . . .	208
	<i>Oral administration</i> . . . . .	208
8.4.	Artificial Cells Containing Genetically-engineered Cells . . . .	209
	<i>General</i> . . . . .	209
	<i>Growth hormone, monoclonal antibodies, factor XI, erythropoietin</i> . . . . .	210
	<i>Neurological disorders</i> . . . . .	210
	<i>Tumors</i> . . . . .	211
	<i>Discussions</i> . . . . .	212
8.5.	Artificial Cells Containing Stem Cells . . . . .	212
8.6.	Artificial Cells Containing Microorganisms . . . . .	213
8.7.	Concluding Remarks . . . . .	216
8.8.	Method I: Standard Alginate-Polylysine-Alginate Method . . . .	217
	<i>Materials</i> . . . . .	217
	<i>Droplet generators</i> . . . . .	217
8.9.	Method II: 2-Step Method . . . . .	219
8.10.	Method III: Preparation of Cells for Encapsulation . . . . .	221
	<i>Preparation of rat hepatocytes</i> . . . . .	221
	<i>Bone marrow stem cells from rats</i> . . . . .	222
	<i>Genetically-engineered E. coli DH5 cells and microorganism</i> . . . .	222
8.11.	Method IV: Artificial Cells with Macromolecular Cutoffs . . . .	223
	<i>Microorganism</i> . . . . .	223
	<i>Procedure</i> . . . . .	224
<b>Chapter 9. Artificial Cells Containing Hepatocytes and/or Stem Cells in Regenerative Medicine</b>		<b>225</b>
9.1.	Introduction . . . . .	225

	<i>Artificial cells and regenerative medicine</i> . . . . .	225
	<i>Design of study</i> . . . . .	227
9.2.	Artificial Cells Containing Hepatocytes . . . . .	228
	<i>Galactosamine-induced fulminant hepatic failure in rats</i> . . . . .	228
	<i>Gunn rats with severe elevation of bilirubin,</i> <i>hyperbilirubinemia</i> . . . . .	229
	<i>Summary</i> . . . . .	231
9.3.	Immunoisolation . . . . .	231
	<i>Can artificial cells protect hepatocytes from immunorejection?</i> . . . . .	231
	<i>Why do rat hepatocytes inside artificial cells recover their</i> <i>viability after implantation into mice?</i> . . . . .	233
	<i>Aggregation of artificial cells after implantation</i> . . . . .	233
	<i>Artificial cells prepared by standard method: cell viability after</i> <i>implantation</i> . . . . .	234
	<i>Artificial cells prepared by two-step method: cell viability after</i> <i>implantation</i> . . . . .	236
9.4.	Artificial Cells Containing Hepatocytes or Hepatocytes Plus Stem Cells . . . . .	236
	<i>Introduction</i> . . . . .	236
	<i>Viability of free cells in culture</i> . . . . .	237
	<i>In vitro viability of encapsulated cells</i> . . . . .	237
	<i>Discussion of above results</i> . . . . .	239
	<i>Study using Gunn rat model</i> . . . . .	240
9.5.	Artificial Cells Containing Hepatocytes in Rats with 90% of Liver Surgically Removed . . . . .	241
	<i>Introduction</i> . . . . .	241
	<i>Artificial cells prepared using 2-step method on survival of rats</i> <i>with 90% of liver surgically removed</i> . . . . .	241
	<i>Factors to be considered</i> . . . . .	242
9.6.	Artificial Cells Containing Bone Marrow Stem Cells . . . . .	243
	<i>Viability of isolated cells</i> . . . . .	244
	<i>Survival rates of rats with 90% of liver surgically removed</i> . . . . .	244
	<i>Remnant liver weight</i> . . . . .	246
	<i>Blood chemistry</i> . . . . .	246
	<i>Plasma hepatic growth factor (HGF) levels</i> . . . . .	246
	<i>Laparotomy and histology</i> . . . . .	247

	<i>Immunocytochemistry</i> . . . . .	249
	<i>PAS glycogen stain</i> . . . . .	249
	<i>Possible mechanisms responsible for recovery of 90% hepatectomized rat model</i> . . . . .	249
9.7.	Artificial Cells Containing Stem Cells in Regeneration Medicine	251
<b>Chapter 10. Hemoperfusion in Poisoning, Kidney Failure, Liver Failure, and Immunology</b>		<b>252</b>
10.1.	Introduction . . . . .	252
	<i>Artificial kidney machine</i> . . . . .	252
	<i>Hemoperfusion based on artificial cells</i> . . . . .	252
10.2.	Development and Clinical Trials . . . . .	253
	<i>Treatment of patients with severe accidental or suicidal poisoning</i> . . . . .	255
	<i>Hemoperfusion for removal of unwanted or toxic substances from blood under other conditions</i> . . . . .	256
	<i>Treatment of patients with terminal kidney failure</i> . . . . .	256
	<i>Treatment of patients with hepatic coma</i> . . . . .	257
	<i>Protein-coated artificial cells in immunoadsorption</i> . . . . .	258
10.3.	Basic Principle of Artificial Cell in Hemoperfusion . . . . .	258
	<i>Permeability and transport characteristics</i> . . . . .	258
	<i>Experimental analysis</i> . . . . .	260
10.4.	Artificial Cells Containing Activated Charcoal in Hemoperfusion . . . . .	261
	<i>Why use activated charcoal for artificial cell hemoperfusion?</i> . . . . .	261
	<i>Effects on embolism</i> . . . . .	262
	<i>Effects of hemoperfusion on platelets</i> . . . . .	262
	<i>Clearance of the ACAC artificial cell artificial kidney</i> . . . . .	263
	<i>Improvements in hydrodynamics</i> . . . . .	265
10.5.	Hemoperfusion in Acute Suicidal or Accidental Poisoning . . . . .	266
	<i>Preclinical studies</i> . . . . .	266
	<i>First clinical trials in acute poisoning</i> . . . . .	266
	<i>Result of clinical trials on 11 adult patients with suicidal or accidental drug poisoning</i> . . . . .	267
	<i>Pediatric patient with accidental theophylline overdose</i> . . . . .	273
	<i>Routine clinical uses in patients around the world</i> . . . . .	275

10.6. Hemoperfusion in Terminal Renal Failure Patients . . . . .	276
10.7. Hemoperfusion Alone Supplemented by Hemodialysis . . . . .	279
<i>General clinical results</i> . . . . .	279
<i>First patient on long-term hemoperfusion</i> . . . . .	279
<i>Hemoperfusion and removal of uremic metabolites</i> . . . . .	283
10.8. Conjoint Hemoperfusion-Hemodialysis . . . . .	283
10.9. Miniaturized Artificial Kidney Based on Hemoperfusion- Ultrafiltration . . . . .	286
10.10. Hemoperfusion in Liver Failure . . . . .	288
<i>First observation of recovery of consciousness in hepatic coma</i> . . . . .	288
<i>Results around the world on effect of hemoperfusion on hepatic     coma</i> . . . . .	290
<i>Control studies in galactosamine-induced hepatic failure rats</i> . . . . .	291
10.11. Immunoabsorption . . . . .	294
<i>Protein coated artificial cells in immunoabsorption</i> . . . . .	294
10.12. Detailed Procedures for the Laboratory Preparation of ACAC Hemoperfusion Device . . . . .	295
<i>The extracorporeal shunt chamber</i> . . . . .	295
<i>Preparation of activated charcoal</i> . . . . .	295
<i>Preparation of artificial cells containing activated charcoal</i> . . . . .	296
<i>Procedure for hemoperfusion</i> . . . . .	297

## **Chapter 11. Perspectives on the Future of Artificial Cells as Suggested by Past Research** **299**

11.1. Introduction . . . . .	299
11.2. Membrane Material . . . . .	300
11.3. Polymeric Membrane . . . . .	300
<i>Porosity of polymeric membrane of artificial cells</i> . . . . .	300
11.4. Lipid Membrane Artificial Cells . . . . .	304
11.5. Artificial Cells with Lipid-Polymer Membrane and Incorporation of Macrocyclic Carrier, Na-K-ATPase and Other Carriers . . . . .	305
<i>Artificial cells with lipid-polymer membrane</i> . . . . .	305
<i>Incorporation of channels into lipid-polymer membrane of     artificial cells</i> . . . . .	307
<i>Incorporation of Na-K-ATPase in the membrane of artificial     cells</i> . . . . .	310
<i>Nanobiosensors</i> . . . . .	312

11.6.	Surface Properties of Artificial Cell Membranes . . . . .	312
11.7.	Drug Delivery . . . . .	314
	<i>General</i> . . . . .	314
	<i>Polymeric semipermeable microcapsules</i> . . . . .	316
	<i>Biodegradable polymeric artificial cells, nanoparticles,</i> <i>nanocapsules</i> . . . . .	316
	<i>Liposomes evolved into lipid vesicles that are lipid membrane</i> <i>artificial cells</i> . . . . .	316
	<i>Polymer(PEG)-lipid membrane artificial cells or PEG-lipid</i> <i>vesicles</i> . . . . .	318
	<i>Polymersomes: polymeric membrane artificial cells</i> . . . . .	319
11.8.	Artificial Cells Containing Multienzyme Systems with Recycling of ATP and NADH . . . . .	320
	<i>Artificial cells containing multienzyme system for recycling of</i> <i>ATP</i> . . . . .	320
	<i>Artificial cells containing multienzyme system for recycling of</i> <i>NAD(P)H</i> . . . . .	320
	<i>Artificial cells containing urease, glutamate dehydrogenase and</i> <i>glucose-6-phosphate dehydrogenase</i> . . . . .	321
	<i>Dextran-NADH retained and recycled inside artificial cells</i> <i>(Fig. 11.4)</i> . . . . .	322
	<i>Multienzyme with NAD-dextran for conversion of waste, urea,</i> <i>into useful essential amino acids</i> . . . . .	324
	<i>Recycling of free NADH retained within the lipid-polymer</i> <i>membrane artificial cells for conversion of urea into amino</i> <i>acid</i> . . . . .	324
	<i>Summary</i> . . . . .	327
11.9.	Artificial Cells Containing Microsomes, Cytosol Ribosomes and Polymerases . . . . .	327
	<i>Introduction</i> . . . . .	327
	<i>Artificial cells containing liver microsomes and cytosol</i> . . . . .	328
	<i>Towards a “living” artificial cell containing polymerases,</i> <i>ribosomes and transcription/translation system</i> . . . . .	328
11.10.	New Generations of Computer System and Nanoscale Robotics Based on Artificial Cells . . . . .	331
11.11.	The Future of Artificial Cells . . . . .	332

<b>Appendix I. 1957 Report on “Method for Preparing Artificial Hemoglobin Corpuscles”</b>	<b>335</b>
ERYTHROCYTES . . . . .	335
1. Structure . . . . .	335
2. Function . . . . .	336
3. Enzymes and inclusion bodies . . . . .	336
HEMOGLOBIN . . . . .	337
1. Molecular structure . . . . .	337
2. Hemoglobin content of the blood . . . . .	337
3. Methemoglobin . . . . .	337
4. Derivatives of hemoglobin . . . . .	338
MEMBRANE . . . . .	338
1. Reason for using collodion membrane . . . . .	338
2. Studies made on collodion membrane . . . . .	339
3. Final constituents of collodion solution used in this experiment . . . . .	339
METHOD . . . . .	340
Method I . . . . .	340
Method II . . . . .	343
Experimentation with collodion . . . . .	343
Method III . . . . .	343
Method IV — successful method . . . . .	344
Procedure . . . . .	345
Proof that collodion membrane is formed . . . . .	347
RESULTS . . . . .	348
i. Size of corpuscles . . . . .	348
ii. Content of corpuscles . . . . .	348
iii. Oxygen content . . . . .	348
DISCUSSIONS . . . . .	350
Transportation of O <sub>2</sub> and CO <sub>2</sub> . . . . .	351
Enzyme systems in the erythrocyte . . . . .	353
Buffering action of erythrocyte . . . . .	353
SUMMARY . . . . .	354
BIBLIOGRAPHY . . . . .	354

<b>Appendix II. Methods not Described in Detail in the 11 Chapters</b>	<b>355</b>
A. EMULSION METHODS FOR ARTIFICIAL CELLS . . . . .	355
A.1. Cellulose nitrate membrane artificial cells of micro dimensions . . . . .	355
A.2. Polyamide membrane artificial cells of micro dimensions .	357
A.3. Lipid-polymer membrane artificial cells of micro dimensions that retain ATP and NAD(P)H . . . . .	360
A.4. Double emulsion methods . . . . .	361
B. DROP METHODS FOR LARGER ARTIFICIAL CELLS . . . . .	362
B.1. Polymer membrane artificial cells . . . . .	362
B.2. Lipid-polymer membrane artificial cells . . . . .	364
B.3. Lipid-polymer membrane artificial cells with macrocyclic carrier . . . . .	365
B.4. Incorporation of Na-K-ATPase to membrane of artificial cells . . . . .	365
B.5. Standard alginate-polylysine-alginate artificial cells (tissues, cells, microorganisms) . . . . .	366
B.6. Two-step method for alginate-polylysine-alginate artificial cells (tissues, cells, microorganisms) . . . . .	372
B.7. Macroporous agar membrane artificial cells . . . . .	374
<b>References</b>	<b>377</b>
<b>Index</b>	<b>441</b>